Tevogen Bio Reports First Quarter 2024 Financial Results
Tevogen Bio Holdings Inc. (TVGN)
Company Research
Source: GlobeNewswire
Confirms liability elimination of $94.9 million and discloses $11.3 million of net incomeReports net cash used for operating activities was $2.1 millionReiterates commitment to both patients and shareholders WARREN, N.J., May 29, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, has announced financial results for the fiscal quarter ended March 31, 2024, and filed its quarterly report on Form 10-Q with the Securities and Exchange Commission. As of March 31, 2024, Tevogen has eliminated $94.9 million in balance sheet liabilities as compared to December 31, 2023, by converting convertible promissory notes into shares of common stock. Separately, on May 10, 2024, Tevogen entered into a binding term sheet with an existing investor for a line of credit for up to $36.0 million to
Show less
Read more
Impact Snapshot
Event Time:
TVGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TVGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TVGN alerts
High impacting Tevogen Bio Holdings Inc. news events
Weekly update
A roundup of the hottest topics
TVGN
News
- Tevogen Bio Leadership Meets Members of U.S. Congress to Advocate for Long COVID Patients and Highlights Achievements and Assets as a Blueprint for Biotech InnovationGlobeNewswire
- Tevogen Bio Secures $6 Million Series C Preferred Stock InvestmentGlobeNewswire
- CORRECTION – Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company's Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares [Yahoo! Finance]Yahoo! Finance
- CORRECTION – Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates Series B Preferred SharesGlobeNewswire
- Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates Series B Preferred SharesGlobeNewswire
TVGN
Sec Filings
- 8/26/24 - Form 424B3
- 8/26/24 - Form 8-K/A
- 8/23/24 - Form 424B3
- TVGN's page on the SEC website